Integrated in Silico Docking and MOMA Simulation Methods Reveal Rottlerin as a Potent Janus kinase 2 (JAK2) Inhibitor

Jyothirmayi Vadapalli, Anuradha Vanam, Noboru Motohashi and Rao Gollapudi
Additional contact information
Jyothirmayi Vadapalli: Acharya Nagarjuna University, Nagarjunanagar, India
Anuradha Vanam: Sri Venkateswara University, India
Noboru Motohashi: Meiji Pharmaceutical University, Japan
Rao Gollapudi: University of Kansas, Lawrence, USA

Biomedical Journal of Scientific & Technical Research, 2018, vol. 11, issue 1, 8216-8225

Abstract: Janus kinase 2 (JAK2) is a prospective drug target for myeloproliferative neoplasms, mainly polycythemia Vera, essential thrombocythemia and primary myelofibrosis disorders...

Keywords: Biomedical Sciences; Biomedical Research; Technical Research; Janus kinase 2; Myelofibrosis; Docking Studies; In Silico; Apigenin; Gandotinib; Ruxolitinib; Rottlerin; Tofacitinib; Wogonin (search for similar items in EconPapers)
Date: 2018
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://biomedres.us/pdfs/BJSTR.MS.ID.002034.pdf (application/pdf)
https://biomedres.us/fulltexts/BJSTR.MS.ID.002034.php (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:abf:journl:v:11:y:2018:i:1:p:8216-8225

DOI: 10.26717/BJSTR.2018.10.002034

Access Statistics for this article

Biomedical Journal of Scientific & Technical Research is currently edited by Robert Thomas

More articles in Biomedical Journal of Scientific & Technical Research from Biomedical Research Network+, LLC
Bibliographic data for series maintained by Angela Roy ().